Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida®) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms

Biochemical profiling of anti-HIV prodrug Elsulfavirine (Elpida®) and its active form VM1500A against a panel of twelve human carbonic anhydrase isoforms

The non-nucleoside reverse transcriptase inhibitor VM1500A is approved for the treatment of HIV/AIDS in its N-acyl sulphonamide prodrug form elsulfavirine (Elpida®). Biochemical profiling against twelve human carbonic anhydrase (CA, EC 4.2.1.1) isoforms showed that while elsulfavirine was a weak inh...

Full description

Bibliographic Details
Main Authors: Claudiu T. Supuran, Alessio Nocentini, Elena Yakubova, Nikolay Savchuk, Stanislav Kalinin, Mikhail Krasavin
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:Journal of Enzyme Inhibition and Medicinal Chemistry
Subjects:
non-nucleoside reverse transcriptase inhibitor
elsulfavirine
n-acyl sulphonamide prodrug
human carbonic anhydrase
isoform selectivity
neuropathic pain
Online Access:http://dx.doi.org/10.1080/14756366.2021.1927007

Internet

http://dx.doi.org/10.1080/14756366.2021.1927007

Similar Items